MEET THE POSTER PRESENTER: This poster describes results of a pilot study examining the feasibility and acceptability of painTRAINER, an automated, internet-based pain coping skills training programs among individuals with lupus. READ MORE

MEET THE POSTER PRESENTER: My poster is about the long-term outcome in patients with NOMID, managed by their local providers. Patients with NOMID present with fever, rashes, meningitis, joint pain, and dysplastic bone lesions. READ MORE

MEET THE POSTER PRESENTER: The poster describes the anatomical distribution of The Mas-related G protein-coupled receptor D (Mrgprd)-expressing nonpeptidergic C-fibers (as subset of NaV1.8 + nociceptors) in healthy and osteoarthritis mouse knee. READ MORE

During the ACR Convergence 2020 Opening Session on Thursday, ACR President Ellen M. Gravallese, MD, talked about how the specialty’s response during the pandemic has provided great hope and will help rheumatology become an even more essential specialty. READ MORE

Diversity is a driver of excellence in medicine, says Marc A. Nivet, EdD, MBA, but for it to be operationalized, a reboot of mindset and an upgrade in systems, structures, and policies are required. READ MORE

The axis of interleukin-23 (IL-23) and interleukin-17 (IL-17), which is central to the pathogenesis of spondyloarthritis, will be part of the focus of an ACR Convergence 2020 session. READ MORE

Not all osteoporosis patients are good candidates for a drug holiday. But for some patients, a holiday reduces the risk of rare side effects along with the burdens of paying for and taking osteoporosis medications. READ MORE

Many patients have seen biologics turn RA, psoriasis, lupus, and other familiar disorders into manageable chronic conditions with occasional flares. But the path from research to treatment is neither swift nor direct. READ MORE

Rheumatologists at some point may be asked to consult and evaluate children with central nervous system (CNS) dysfunction related to anautoinflammatory disease, and a session at ACR Convergence 2020 will help rheumatologists learn how to offer needed support. READ MORE

MEET THE POSTER PRESENTER: In SLE, HCQ greatly reduces lupus flares, but long term, this drug may cause irreversible retinal damage leading to vison loss, and there is no treatment for HCQ retinal toxicity other than discontinuing the drug to prevent further damage. READ MORE